B. Riley Securities Reiterates Buy Rating on Nutex Health Inc.
B. Riley Securities maintains its buy rating on Nutex Health Inc. with a $290 price target, a 72.16% upside from the current price.
Key Points
- B. Riley Securities reiterated its buy rating on Nutex Health Inc. (NUTX) on June 26, 2026, with a price target of $290.
- B. Riley Securities's $290 price target implies 72.16% upside from Nutex Health Inc.'s ($NUTX) current $168.45 share price.
- Nutex Health Inc. shares traded at $161.68 on Saturday, with a market cap of approximately $1.15 billion and a P/E ratio of 12.17.
- Key insider purchases at Nutex Health include CEO Dr. Thomas Vo buying 75,747 shares on May 28, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B. Riley Securities has reiterated its buy rating on Nutex Health Inc. (NasdaqCM: NUTX) with a price target of $290. This analyst action was announced on June 26, 2026, by Anderson Schock.
B. Riley Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Nutex Health Inc. Stock Down 11.0%
Shares of NasdaqCM:NUTX traded near $161.68 on Saturday. Nutex Health Inc. has a market cap of approximately $1.15 billion, a P/E ratio of 12.17, and a beta of 2.057. The stock's 52-week range spans from $77.21 to $193.07. Its 50-day moving average is $129.59, and the 200-day moving average is $124.68. The company shows a strong financial position with a current ratio of 3.14 and a quick ratio of 3.0, while its debt-to-equity ratio stands at 78.97.
$NUTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Nutex Health Inc. reported revenue of about $880 million, showing a 2.2% growth. The company's net margin is 10.95%, with a return on equity of 53.65%. The next earnings report is expected on July 30, 2026.
Insider Buying and Selling at Nutex Health Inc.
Recent insider transactions at Nutex Health include CEO Dr. Thomas Vo purchasing 75,747 shares on May 28, 2026. Other notable buys include Kelvin Spears acquiring 2,519 shares on June 4, 2026, and Cheryl Yvonne Grenas, Frank Jaumot, Michael Lee Reed, and Scott Saunders each buying 823 shares on April 23, 2026.
Analysts Set New Price Targets
On June 26, 2026, B. Riley Securities reiterated its buy rating on Nutex Health with a $290 price target. Earlier, on June 2, 2026, Lake Street initiated coverage with a buy rating and a $235 target. The consensus among analysts is a buy rating, with a mean target price of $235.50 based on four opinions.
About Nutex Health Inc.
Nutex Health Inc., based in Houston, Texas, operates in the healthcare sector, specifically in medical care facilities. The company manages a network of micro hospitals and specialty hospitals, providing services such as emergency care and imaging. Nutex also offers population health management services and operates a real estate segment that owns hospital properties. Founded in 2011, Nutex Health is led by CEO Dr. Thomas T. Vo.
Bottom Line
B. Riley Securities' reaffirmation of its buy rating on Nutex Health Inc. with a $290 price target underscores the firm's confidence in the company's growth potential. Investors closely monitor such analyst ratings and insider transactions for insights into the company's prospects. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect the current market conditions.
Get Nutex Health Inc. alerts
New 13F filings, insider trades, and analyst moves on $NUTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.